SCND · Scientific Industries Inc
The latest filing states the doubt was alleviated.
“The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for at least one year after the date the Unaudited Condensed Consolidated Financial Statements are issued. The Company has recorded recurring losses from operations and continued cash outflow from operating activities as a result of its strategic focus on the Bioprocessing Systems Operations, which is still in its start-up stage. Historically the Company has relied on equity financings to support its business operations. For the six months ended June 30, 2026, the Company generated negative cash flows from operations of $1,897,600. The Company has an accumulated deficit of $37,974,000 as of June 30, 2026, and expects to continue to generate negative cash flows from operations in the foreseeable future; however, based on management's current operating plan, the Company expects that the cash generated from the Laboratory Equipment Operations' Genie Division sale during fiscal 2025 (refer to Note 11), plus other incoming cash related to the various post Genie Division-sale agreements and escrow account, is sufficient to support business operations for at least one year from the date of issuance of the Unaudited Condensed Consolidated Financial Statements for the six months ended June 30, 2026; however, there is no assurance that management's current operating plan will be successful.”View the 10-Q filed Aug 14, 2026
2 customers — 49% of revenue (the three months ended June 30, 2026)
“For the three months ended June 30, 2026, two customers accounted for approximately 49% of the Company’s total revenue.”
2 customers — 35% of revenue (the six months ended June 30, 2026)
“For the six months ended June 30, 2026, two customers accounted for approximately 35% of the Company’s total revenue.”
One customer — 10% of revenue (the six months ending June 30, 2025)
“For the six months ending June 30, 2025, one customer accounted for approximately 10% of the Company’s total revenue.”
One customer — 10% of revenue (the three months ending June 30, 2025)
“For the three months ending June 30, 2025, one customer accounted for approximately 10% of the Company’s total revenue.”
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
| Executive | Role | Total |
|---|---|---|
| John A. Moore | Chairman, President of SBI | $259,900 |
| Helena R | Santos, CEO, President, CFO | $258,200 |
| Karl D | Nowosielski, President of Torbal Division and Director of Marketing | $193,300 |
| Robert P | Nichols, President of Genie Division and Corporate Secretary | $177,900 |
| Executive | Role | Total |
|---|---|---|
| Helena R | Santos, CEO, President, CFO | $198,300 |
| Karl D | Nowosielski, President of Torbal Division and Director of Marketing | $187,100 |
| Robert P | Nichols, President of Genie Division and Corporate Secretary | $168,300 |
| John A. Moore | Chairman, President of SBI | $61,800 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Zachary Rovinsky | Chief Financial Officer | Appointed | 2025-08-27 |
| Nicholas Lavacca | Chief Financial Officer | Resigned | 2025-05-21 |
| Nicholas Lavacca | Chief Financial Officer | Appointed | 2025-04-02 |
| Michael Blechman | Class B Director | Appointed | 2024-04-15 |
| Marcus Frampton | Class B Director of the Company's Board of Directors | Resigned | 2024-04-08 |
| John Nicols | Chairman of the Board of Directors of SBI | Appointed | 2024-03-07 |
| John Nicols | member of the Board's compensation committee | Appointed | 2024-03-07 |
| John Nicols | member of the Board's audit committee | Appointed | 2024-03-07 |
| John Nicols | Class C Director | Appointed | 2024-03-07 |
| Joseph G. Cremonese | member of the Company's Class C Board of Directors | Retired | 2023-06-14 |
| Reginald Averilla | Chief Financial Officer | Appointed | 2022-04-13 |
| Daniel Gruenes | SBI's new Chief Executive Officer and President | Appointed | 2022-04-05 |
| John A. Moore | SBI's Chairman | Appointed | 2022-04-05 |
| Reinhard Vogt | Chairman of the Company's indirect wholly-owned subsidiary, Scientific Bioprocessing Inc. ("SBI") | Resigned | 2022-04-05 |
| Reinhard Vogt | Class A Director | Resigned | 2022-04-05 |
| Dr. Jürgen Schumacher | Board of Directors | Appointed | 2021-04-30 |
| Dr. Jürgen Schumacher | Class A Director | Appointed | 2021-04-30 |
| Christopher Cox | Class C Director | Appointed | 2021-03-01 |
| Joseph G. Cremonese | Class C Director | Appointed | 2021-03-01 |
| John F.F. Watkins | Class C Director | Resigned | 2021-01-08 |
| Reinhard Vogt | Director | Appointed | 2020-07-22 |
| Reinhard Vogt | chairman of the Board of Directors of SBI | Appointed | 2020-07-22 |
| James S. Segasture | Class A Director | Resigned | 2020-07-22 |
| Brookman P. March | Vice President-Corporate Strategy and Vice President of Sales | Terminated | 2020-02-18 |